Oncology
Congress Materials
The content contained herein is for educational purposes only. No reproduction, alteration, or distribution of this information is permitted. Relacorilant (LIFYORLI™) is U.S. FDA approved for use in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian cancer who have received 1-3 prior systemic treatment regimens, at least one of which included bevacizumab. All other indications are under investigation, and the safety and efficacy of such investigational uses have not been established by the FDA, EMA, or any regulatory authority. There is no guarantee that these products will be approved for the indications under investigation.
Access Corcept oncology congress presentations below.
Filter by:
European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress
2026
Efficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10)
Olawaiye AB, Derquin F, Taylor NP, et al.
European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress
2026
Real-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0)
Shahin MS, Snider J, Parthan A, et al.
American Society of Clinical Oncology (ASCO) Annual Meeting
2026
SYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid Malignancies
Hamid O, Pacheco JM, Chandana SR, et al.
American Society of Clinical Oncology (ASCO) Annual Meeting
2026
TRIDENT: A Phase 2 Study of Relacorilant Plus Nab-paclitaxel and Gemcitabine in Chemotherapy-naïve Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Borazanci EH, Rasco DW, Kasi A, et al.
American Society of Clinical Oncology (ASCO) Annual Meeting
2026
Overall Survival Subgroup Analyses for Prior Taxane Use in the Phase 3 ROSELLA Trial of Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer
Gilbert L, You B, Olawaiye AB, et al.
Society of Gynecologic Oncology (SGO) Annual Meeting
2026
Real-World Comparative Effectiveness of Nab-Paclitaxel and Paclitaxel in Combination with Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer (COMPASS)
Coleman RL, Mathur R, Parthan A, et al.
Society of Gynecologic Oncology (SGO) Annual Meeting
2026
Relacorilant Plus Nab-Paclitaxel Demonstrates a Progression-Free Survival Benefit in Ovarian Cancer Independent of Tumor Glucocorticoid Receptor (GR) Expression Levels
Lorusso D, Fleming GF, Colombo N, et al.
Society of Gynecologic Oncology (SGO) Annual Meeting
2026
BELLA: A Phase 2 Study of Relacorilant + Nab-Paclitaxel +/- Bevacizumab in Patients with Gynecologic Cancers
Lorusso D, Monk BJ, Park JY, et al.
Society of Gynecologic Oncology (SGO) Annual Meeting
2026
Final Overall Survival Results from the Phase 3 ROSELLA Trial: Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer
Olawaiye AB, Quesada S, Gilbert L, et al.
European Society of Gynaecological Oncology (ESGO) Congress
2026
Relacorilant + Nab-Paclitaxel vs Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer: Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Exposure-Response
Colombo N, Botbyl J, Kesner-Hays A, et al.
European Society of Gynaecological Oncology (ESGO) Congress
2026
ROSELLA: A Phase 3 Study of Relacorilant + Nab-Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023)
Lorusso D, Quesada S, Chan JK, et al.
International Gynecologic Cancer Society (IGCS) Annual Global Meeting
2025
Phase 3 ROSELLA (GOG-3073, ENGOT-ov72) Trial of Relacorilant + Nab-paclitaxel vs Nab-paclitaxel in Platinum-resistant Ovarian Cancer: Primary Results and Outcomes in Older Patients
Olawaiye AB, Gladieff L, Gilbert L, et al.
European Society for Medical Oncology (ESMO) Congress
2025
ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + Nab-Paclitaxel in the Subgroup of Patients With Platinum-Resistant Ovarian Cancer (PROC) Previously Exposed to a PARP Inhibitor
Lorusso R, Quesada S, Chan JK, et al.
European Society for Medical Oncology (ESMO) Congress
2025
BELLA: A Phase 2 Study of Relacorilant + Nab-Paclitaxel +/- Bevacizumab in Patients with Gynecologic Cancers
Lorusso D, Monk BJ, Park JY, et al.
European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress
2025
Comparative Effectiveness of Nab-Paclitaxel and Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (COMPASS)
Shahin MS, Mathur R, Parthan A, et al.
European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress
2025
Phase 3 Results of Relacorilant + Nab-Paclitaxel v Nab-Paclitaxel In Platinum-Resistant Ovarian Cancer (ROSELLA): Secondary Endpoints
Lorusso D, Gladieff L, Gilbert L, et al.
American Society of Clinical Oncology (ASCO) Annual Meeting
2025
ROSELLA: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer
Olawaiye AB, Gladieff L, Gilbert L, et al.
Society of Gynecologic Oncology (SGO) Annual Meeting
2024
Final Overall Survival Data From a Randomized, Open-Label, Phase 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Patients With Recurrent Platinum-Resistant Ovarian Cancer
Colombo N, Van Gorp T, Matulonis UA, et al.
International Gynecologic Cancer Society (IGCS) Annual Global Meeting
2023
ROSELLA (GOG-3073, ENGOT-OV72/MITO): A Phase 3 Study of Relacorilant + Nab-paclitaxel vs. Nab-paclitaxel in Platinum-Resistant Ovarian Cancer
Lorusso D, Bagameri A, Bishop E, et al.
European Society of Gynaecological Oncology (ESGO) Congress
2023
ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer
Lorusso D, Bagameri A, Bishop E, et al.
American Association for Cancer Research (AACR) Annual Meeting
2023
Selective Glucocorticoid Receptor Modulation Reveals a New Role for CLEC10A in Patients With Solid Tumors
Colombo N, Van Gorp T, Matulonis UA, et al.
Society of Gynecologic Oncology (SGO) Annual Meeting
2023
ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer
Olawaiye AB, Van Gorp T, Monk BJ, et al.
American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
2023
Phase 1 Efficacy and Pharmacodynamic Results of Exicorilant + Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Morris MJ, Linch M, Crabb SJ, et al.
International Gynecologic Cancer Society (IGCS) Annual Global Meeting
2022
Phase 2 Results of Relacorilant + Nab-Paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer with and Without Prior Bevacizumab
Colombo N, Van Gorp T, Matulonis UA, et al.
European Society for Medical Oncology (ESMO) Congress
2022
Glucocorticoid Receptor Expression and Activity in a Phase 2 Ovarian Cancer Trial of the Glucocorticoid Receptor Modulator Relacorilant in Combination with Nab-Paclitaxel
Lorusso D, Greenstein AE, Wadekar S, et al.
European Society for Medical Oncology (ESMO) Congress
2022
Phase 1 Results of Exicorilant + Enzalutamide in Patients with Castration-Resistant Prostate Cancer
Linch M, Liu G, Crabb SJ, et al.
European Society for Medical Oncology (ESMO) Congress
2022
Relacorilant + Nab-paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer: Phase 2 Subgroup Analysis Mirroring the Patient Population of an Upcoming Phase 3 Study
Colombo N, Van Gorp T, Matulonis UA, et al.
American Society of Clinical Oncology (ASCO) Annual Meeting
2022
Overall survival data from a 3-arm randomized phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer
Colombo N, Van Gorp T, Matulonis UA, et al.
American Society of Clinical Oncology (ASCO) Annual Meeting
2022
A study of relacorilant in combination with nab-paclitaxel in metastatic pancreatic ductal adenocarcinoma (mPDAC)
Borazanci EH, Bahary N, Chung V, et al.
European Society for Medical Oncology (ESMO) Congress
2021
Relacorilant, A Selective Glucocorticoid Receptor Modulator, In Combination With Nab-Paclitaxel Improves Progression-Free Survival In Patients With Recurrent Platinum-Resistant Ovarian Cancer: A 3-Arm, Randomized, Open-Label, Phase 2 Study
Lorusso D, Colombo N, Nguyen D, et al.
American Association for Cancer Research (AACR) Annual Meeting
2020
Suppression of Tumor Immune Activity in Adrenocortical Carcinoma with Excess Glucocorticoid
Greenstein AE, Habra MA, Mura M, et al.
American Society of Clinical Oncology (ASCO) Annual Meeting
2020
Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol
Greenstein AE, Munster PN, Sachdev JC, et al.
American Society of Clinical Oncology (ASCO) Annual Meeting
2019
Relacorilant With Nab-paclitaxel: Safety and Activity in Patients With Pancreatic Ductal Adenocarcinoma and Ovarian Cancer
Munster PN, Sachdev JC, Fleming GF, et al.
San Antonio Breast Cancer Symposium (SABCS)
2013
A randomized phase I trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel, Abraxane®) with or without mifepristone for advanced breast cancer
Nanda R, Chennamaneni P, Gibson J, et al.